| Popis: |
Objectives: To describe the clinical and sub-clinical features in patients with Systemic Lupus Erythematosus (SLE) according to the criteria of the ACR/SLICC 2015, studying the relationship between clinical and sub-clinical features. Methods: This was a descriptive cross - sectional study of 74 SLE patients admitted to Nephrology – Rheumatology Department of Hue Central Hospital and General Medicine - Endocrinology Department of Hue University of Medicine and Pharmacy Hospital from March 2020 to March 2021. Results: Malar rash 70.3%, photosensitivity 66.2%, discoid rash 18.9%, non – scarring alopecia 75.7%, oral ulcers 21.6%, arthritis 54.1%, serositis 2.7%, neurology and/or psychosis damage 5.4%, kidney involvement 75.7%, hematologic: leukopenia 40.5%, lymphopenia 56.8%, thrombocytopenia 41.9%, hemolytic anemia 16.2%, positive ANA 74.3%, positive anti-dsDNA 64.9%. Positive ANA in non – scarring alopecia group was higher than the group without (p < 0.05); positive anti-dsDNA in malar rash group was higher than the group without (p < 0.05); the risk of kidney involvement was higher in the group with positive anti-dsDNA (OR = 3.1; p < 0.05), the rates of anemia and thrombocytopenia in kidney involvement groups were higher than the group without (p < 0.05). Conclusions: In this study cohort, the clinical, subclinical features according to the criteria of the ACR/ SLICC 2015 that had the highest rate were non – scarring alopecia and kidney involvement, followed by malar rash, photosensitivity. ANA positivity in the non-scarring alopecia group was higher. Anti-dsDNA positivity in malar rash group was higher. The risk of potential kidney disorders was higher in the group with positive anti-dsDNA. The rates of anemia and thrombocytopenia in the potential kidney disorders group were higher. Key words: Systemic Lupus Erythematosus, ACR/SLICC 2015, ANA, anti ds DN |
